Related references
Note: Only part of the references are listed.Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial
Annalisa Chiappella et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease
Thomas E. Lew et al.
BONE MARROW TRANSPLANTATION (2021)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
p53 is associated with high-risk and pinpointsTP53missense mutations in mantle cell lymphoma
Joana M. Rodrigues et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule et al.
HAEMATOLOGICA (2019)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Subclonal TP53 copy number is associated with prognosis in multiple myeloma
Vallari Shah et al.
BLOOD (2018)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Christian W. Eskelund et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Marie-Helene Delfau-Larue et al.
BLOOD (2015)
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
A. M. Halldorsdottir et al.
LEUKEMIA (2011)
TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis
D. Bowen et al.
LEUKEMIA (2009)
Share Paper
